Interleukin-2 in an alternative dose (the Iliad trial): treatment of patients with metastatic renal cell carcinoma with low dose proleukin.
Phase of Trial: Phase IV
Latest Information Update: 27 Jan 2014
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms ILIAD
- 27 Jan 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
- 17 Sep 2005 New trial record.